Ipca Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Ipca Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 1591.25, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.25% on the day, quoting at 23745.85. The Sensex is at 78340.19, up 1.29%. Ipca Laboratories Ltd has slipped around 1.43% in last one month.

Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has slipped around 5.27% in last one month and is currently quoting at 21544.15, up 1.67% on the day. The volume in the stock stood at 2.47 lakh shares today, compared to the daily average of 3.37 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 1593.75, up 1.8% on the day. Ipca Laboratories Ltd is up 50.01% in last one year as compared to a 20.57% spurt in NIFTY and a 38.57% spurt in the Nifty Pharma index.

The PE of the stock is 56.98 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

Ipca Laboratories has fixed 27 November 2024 as record date for interim dividend for FY 2024-25.

Powered by Capital Market - Live News

Ipca Laboratories announced that the Board of Directors of the Company at its meeting held on 14 November 2024, has recommended a Interim dividend of Rs.2 per share (i.e.200%), subject to the approval of the shareholders.

Powered by Capital Market - Live News

Profit before tax surged 53.01% to Rs 344.83 crore in the September 2024 quarter from Rs 225.36 crore posted in Q2 FY24.

EBITDA before forex gain/ (loss), other income and exceptional items stood at Rs 449.83 crore, registering a growth of 25% YoY.

During the quarter, total formulations were at Rs 1,482.01 crore, up 13% YoY. Domestic stood at Rs 940.51 crore (up 11% YoY) and exports came in at Rs 541.50 crore (up 15.03% YoY) in Q2 FY25.

On half yearly basis, the company’s consolidated net profit grew 36.97% to Rs 421.71 crore on 22.89% increase in revenue from operations to Rs 4,447.53 crore in H1 FY25 over H1 FY24.

Meanwhile, the firm’s board has declared an interim dividend of Rs 2 per equity share for the financial year ended 2024-25. The firm had already fixed 28 October 2024 as record date for interim dividend and it will be paid on or before 10 December 2024.

Ipca Laboratories is an Indian multinational pharmaceutical company. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally.

Powered by Capital Market - Live News